Recent trial data indicate that axillary lymph node dissection (ALND) can be safely omitted in select patients, according to a research presented at the 2015 San Antonio Breast Cancer Symposium.
The use of sentinel lymph node biopsy (SLNB) alone for care for axillary management in breast cancer patients with negative nodes is on the increase, according to study data presented at the 2015 San Antonio Breast Cancer Symposium.
New study findings presented at SABCS 2015 suggest that BRCAT431 promotes tamoxifen resistance, thereby increasing the clinical risk of recurrence and metastases in breast cancer.
A novel genetic driver analysis of matched breast cancer primary tumors and multiorgan metastases suggests that most genetic drivers in a single tumor are based on DNA copy number variants (CNV), are established early, and are maintained in metastases. These findings were presented at the 2015 San Antonio Breast Cancer Symposium.
Breast-conserving surgery with radiation therapy (BCT) demonstrated improved 10-year overall survival in patients with early stage breast cancer compared with mastectomy without radiation therapy, according to data presented at the 2015 San Antonio Breast Cancer Symposium.
EndoPredict (EP) provided superior information to the Oncotype DX recurrence score (RS) for distant recurrence (DR) in overall, N+, and N- patient populations, and also pinpointed a low-risk patient group who may not need chemotherapy.
Use of a synthetic 2D mammogram, instead of a standard 2d film, may offer breast cancer patients the benefits of 2D/3D screening combinations at a reduced radiation exposure level.
Carboplatin added to anthracycline/taxane-based neoadjuvant chemotherapy significantly improved pathological complete response rates in patients with triple-negative breast cancer in two large phase IIb studies: GeparSixto and CALGB 40603. Researchers reported on disease-free survival for GeparSixto after median 35 months of observation at the 2015 San Antonio Breast Cancer Symposium.
Premenopausal women with luminal A subtype breast cancer had comparable 10-year disease-free survival rates regardless of whether they received adjuvant chemotherapy, according to data presented at the 2015 San Antonio Breast Cancer Symposium.
Prophylactic use of standard HF pharmacotherapy appears to be effective for patients with HER2-overexpressing breast cancer.
